Dianthus Therapeutics (NASDAQ:DNTH) Given New $36.00 Price Target at Wedbush

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective cut by Wedbush from $38.00 to $36.00 in a research note released on Friday, Benzinga reports. They currently have an outperform rating on the stock.

Several other equities analysts have also recently commented on DNTH. Raymond James boosted their target price on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the company an outperform rating in a research report on Thursday, April 18th. HC Wainwright started coverage on Dianthus Therapeutics in a research note on Thursday, May 16th. They set a buy rating and a $40.00 target price for the company. Cantor Fitzgerald assumed coverage on Dianthus Therapeutics in a report on Thursday, June 27th. They issued an overweight rating on the stock. Baird R W upgraded Dianthus Therapeutics to a strong-buy rating in a research report on Friday, July 26th. Finally, Lifesci Capital upgraded Dianthus Therapeutics to a strong-buy rating in a research report on Tuesday, June 11th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Buy and a consensus price target of $44.71.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $26.47 on Friday. The firm has a market cap of $776.87 million, a PE ratio of -4.54 and a beta of 1.89. The stock’s fifty day moving average price is $26.43 and its two-hundred day moving average price is $25.16. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The company had revenue of $1.86 million during the quarter, compared to the consensus estimate of $0.63 million. Sell-side analysts expect that Dianthus Therapeutics will post -2.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DNTH. Bain Capital Life Sciences Investors LLC bought a new stake in Dianthus Therapeutics during the 1st quarter worth approximately $89,761,000. RA Capital Management L.P. acquired a new stake in Dianthus Therapeutics in the first quarter valued at $69,990,000. Vanguard Group Inc. raised its position in Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Dianthus Therapeutics during the 1st quarter worth about $11,251,000. Finally, Vestal Point Capital LP bought a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at about $1,404,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.